AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino Santini
GlobeNewswire - Wed Apr 16, 6:49PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new appointments to its board of directors. Current board member, Gino Santini, has been elected, by unanimous vote, to chairman of the board of directors, effective immediately, taking over for Mike Narachi. Mr. Narachi informed the board that, after eight years of service, he has decided not to stand for re-election at this year's upcoming annual shareholder meeting in May 2014. In addition, James R. Sulat has been elected to serve as a new member of the board of directors, effective immediately.
AMAG Pharmaceuticals Has Returned 28.6% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Mon Apr 14, 4:46PM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 28.57% as of today's recent price of $17.26.
AMAG Pharmaceuticals Shares Down 25.1% Since SmarTrend's Sell Call (AMAG)
Comtex SmarTrend(R) - Mon Apr 07, 11:06AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 25.10% as of today's recent price of $18.10.
AMAG Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 4:00PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the 13 Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 2:20 p.m. ET in New York. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed.
20.5% Return Seen to Date on SmarTrend AMAG Pharmaceuticals Call (AMAG)
Comtex SmarTrend(R) - Mon Mar 31, 9:47AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 20.55% as of today's recent price of $19.20.
AMAG Pharmaceuticals Has Returned 13.7% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Mon Mar 24, 9:27AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 13.72% as of today's recent price of $20.85.
Concise Analysis of the International Intravenous (IV) Iron Drugs Industry
M2 - Tue Mar 11, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8bxct/intravenous_iv) has announced the addition of the "Concise Analysis of the International Intravenous (IV) Iron Drugs Industry" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 20 companies including many key and niche players such as: - Actavis, Inc. - AMAG Pharmaceuticals, Inc. - Fresenius Medical Care AG & Co. - KGaA Galenica Ltd. - Vifor Pharma Ltd. - Luitpold Pharmaceuticals, Inc. - American Regent, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview & Trends 3. Regulatory Overview 4. Overview Of Intravenous (Iv) Iron Drugs 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 20 (including Divisions/Subsidiaries - 22) - The United States (
Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare
PR Newswire - Thu Mar 06, 10:50AM CST
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Shares of AMAG Down 12.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 28, 9:33AM CST
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 4 months, AMAG Pharmaceuticals has returned 12.64% as of today's recent price of $21.11.
AMAG Pharmaceuticals, Inc. to Participate in the Cowen and Company 34th Annual Healthcare Conference
GlobeNewswire - Thu Feb 27, 8:52AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Cowen and Company 34 Annual Healthcare Conference on Monday, March 3, 2014 at 4:10 p.m. ET in Boston. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed.
AMAG Pharmaceuticals names Edward Jordan as SVP of Sales and Marketing
M2 - Wed Feb 26, 3:16AM CST
Pharmaceutical company AMAG Pharmaceuticals (NasdaqGS:AMAG) reported on Tuesday the election of Edward Jordan as senior vice president of its sales and marketing.
AMAG Pharmaceuticals Appoints Edward Jordan as Senior Vice President of Sales and Marketing
GlobeNewswire - Tue Feb 25, 7:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Edward Jordan as senior vice president of sales and marketing. Mr. Jordan brings to AMAG more than 20 years of experience in U.S. and international pharmaceutical sales and marketing operations. Prior to joining AMAG, Mr. Jordan served as head of sales, marketing, and operations of the women's health division at Teva Pharmaceuticals. In this role he led sales, marketing, training, and sales analytics for their branded pharmaceuticals, over-the-counter products and a medical device.
Mintz Levin Named Biotechnology "Law Firm of the Year- North America" by M&A Today Global Awards
Business Wire - Fri Feb 21, 11:46AM CST
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. announced that it has been recognized by M&A Today's Global Awards as the 2014 "Law Firm of the Year (Biotechnology) - North America." M&A Today's Global Awards program identifies "industry leaders, exemplary teams and distinguished organizations, based on the simple principles of veracity, accuracy and insight."
Study Shows MuGard(R) is More Effective Than Sham-Control at Reducing Mouth and Throat Soreness Associated With Oral Mucositis in Head and Neck Cancer Patients
GlobeNewswire - Tue Feb 18, 7:01AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the publication of data from a multi-institutional trial of MuGard in the online edition of the journal Cancer available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full. MuGard is a mucoadhesive hydrogel. The randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing pain associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.
Spanning and CloudLock to Present "How to Prevent Data Loss and Ensure Compliance for Your SaaS Applications"
Business Wire - Thu Feb 13, 8:00AM CST
Spanning Cloud Apps, the leading provider of data backup and recovery for cloud applications, will join CloudLock, the cloud security pioneer and the world's leading cloud data security company, to demonstrate how organizations can proactively take control of their SaaS applications, preventing data loss and maintaining security and compliance. The webinar, "How to Prevent Data Loss and Ensure Compliance for Your SaaS Applications," will feature AMAG Pharmaceuticals. The company will explain how they effectively implemented backup and recovery for Google Apps and are enforcing data loss prevention policies in Google Drive. Attendees will learn how to mitigate the risks of data leakage and loss, while improving business continuity.
AMAG Pharmaceuticals (AMAG) Falls: Crumbles 5.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:38AM CST
AMAG Pharmaceuticals, Inc. (AMAG) saw a big move last session, as the company’s shares fell by more than 5% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for AMAG, as the stock is now down roughly 13% since Jan 15.
AMAG Pharmaceuticals Announces Pricing of $175 Million of 2.50% Convertible Senior Notes Due 2019
GlobeNewswire - Wed Feb 12, 5:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the pricing of $175 million aggregate principal amount of 2.50% Convertible Senior Notes due 2019 (the "notes"